Aktie A2DSTM CAPLIN POINT LABORATORIES LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Caplin Point Laboratories Limited

Aktien

A2DSTM

INE475E01026

CAPLIPOINT

Markt geschlossen - Bombay S.E.
Andere Börsenplätze
 12:00:49 26.04.2024 		% 5 Tage % 1. Jan.
1’350 INR -0.48% Intraday Chart für Caplin Point Laboratories Limited +2.69% -0.42%
28.03. Caplin Point Unit erhält US FDA-Zulassung für Augenbehandlungsmedikament MT
28.03. Caplin Steriles Limited, eine Tochtergesellschaft von Caplin Point Laboratories Limited, erhält USFDA-Zulassung für Ketorolac Tromethamin Augenheilmittel CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Caplin Point Arm Gets US FDA Final Nod for Ofloxacin Ophthalmic Solution
Caplin Point Unit Receives US FDA Nod for Eye Treatment Medication
Caplin Steriles Limited, A Subsidiary of Caplin Point Laboratories Limited Gets USFDA Approval for Ketorolac Tromethamine Ophthalmic Solution
Caplin Point Laboratories Arm Starts Operations of Oncology Facility at Kakkalur, India
Caplin One Labs Limited, a Wholly Owned Subsidiary of Caplin Point Laboratories Limited Successfully Completes New Oncology (Anti-Cancer) Facility, Commences Operations
Caplin Point Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Caplin Point Laboratories to Invest INR7 Billion in Tamil Nadu, India
Caplin Point Unit Gets US FDA Final Approval for Generic Ear Infection Drug
Caplin Point Laboratories Limited Announces Resignation of Hero Velladurai as President, R&D
Caplin Point Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023
Caplin Point Unit's Injectable and Ophthalmic Plant in India Gets VAI Classification from US FDA
Caplin Point Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023
Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023
Caplin Point Laboratories to Incorporate Step-Down Subsidiary in US
Caplin Point Unit Gets US FDA Nod for Muscle Relaxant
Caplin Steriles Limited Gets United States Food and Drug Administration Approval for Cisatracurium Besylate Injection USP
Caplin Point Gets Four Observations from US FDA After Inspection of Injectable Unit at Gummidipoondi, India
Caplin Point Laboratories Limited Approves Interim Dividend for the Financial Year 2022-23
Caplin Point Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2DSTM Aktie
  4. Nachrichten Caplin Point Laboratories Limited
  5. Andere Sprachen